Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 10/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18921413 | 0.87 | RIPK1 (0.38) | RIPK1 | |
| SCHEMBL18921415 | 0.87 | RIPK1 (0.38) | RIPK1 | |
| SCHEMBL25816471 | 0.84 | GPR119 (0.34) | — | |
| SCHEMBL29048222 | 0.84 | GPR119 (0.34) | — | |
| SCHEMBL29048214 | 0.84 | GPR119 (0.34) | — | |
| SCHEMBL18921388 | 0.82 | RIPK1 (0.35) | RIPK1 | |
| Hydrochloric Acid SCHEMBL30339153 | 0.75 | — | — | |
| SCHEMBL18921315 | 0.75 | RIPK1 (0.36) | RIPK1 | |
| SCHEMBL18921288 | 0.74 | RIPK1 (0.38) | RIPK1 | |
| SCHEMBL18921378 | 0.74 | RIPK1 (0.37) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108602809-B | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1(RIPK 1) | 戴纳立制药公司 | 2022-09-30 | — | — | CN | disclosed |
| US-10709692-B2 | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) | DENALI THERAPEUTICS INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10709692-B2 | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) | DENALI THERAPEUTICS INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20180353480-A1 | ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK1) | APTUIT (VERONA) S.R.L. (IT) | 2018-12-13 | — | — | US | disclosed |
| WO-2017096301-A1 | ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK 1) | DENALI THERAPEUTICS INC. (US) | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180353480-A1 | ISOXAZOLIDINE DERIVED INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE 1 (RIPK1) | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
| US-10709692-B2 | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.